The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor

ConditionFibromyalgia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorKanuni Sultan Suleyman Training and Research Hospital

About this trial

Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified.

Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.

Eligibility criteria

Qualifiers

Female participants aged between 18 and 50 years

Disqualifiers

None

Trial design

Treatments tested in this trial

  • No Intervention (Observational Study)

Treatment groups

60 Participants
are divided into 2 treatment groups